









Markets
/
Stocks
/
nasdaq-iccm
/

Icecure Medical Ltd

ICCM



View Detailed Chart

0.675USD

+0.010+1.52%

Close 12/19, 16:00（ET）Quotes delayed by 15 min

46.54MMarket Cap

LossP/E TTM



Icecure Medical Ltd

0.675

+0.010+1.52%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

+1.52%

5 Days

+1.61%

1 Month

+3.99%

6 Months

-29.05%

Year to Date

-38.65%

1 Year

-39.74%

View Detailed Chart

TradingKey Stock Score of Icecure Medical Ltd

Currency: USD Updated: 2025-12-19

Key Insights

Icecure Medical Ltd's fundamentals are relatively very healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 116/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is low.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.12.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Icecure Medical Ltd's Score

Industry at a Glance

Industry Ranking

116 / 208

Overall Ranking

274 / 4582

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

3.125

Target Price

+356.60%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Icecure Medical Ltd Highlights

StrengthsRisks

Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.

Growing

The company is in a growing phase, with the latest annual income totaling USD 3.29M.

Overvalued

The company’s latest PE is -2.60, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 241.02K shares, decreasing 18.19% quarter-over-quarter.

Held by Ken Fisher

Star Investor Ken Fisher holds 0.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.36.